Skip to main content
Explore URMC
menu

Megan A. Baumgart, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-9319

Fax: (585) 273-5761

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

I chose the field of oncology because I want to help patients through one of the most difficult experiences a person can have.

Cancer treatment requires a team approach involving the patient, medical oncologist, nurses and support staff, as well as other medical teams such as radiation oncology and surgery who are often part of a patient's care. I work with patients to help them understand the overall treatment plan – especially the role of chemotherapy in the treatment of their disease – and support them throughout the course of treatment.

I am optimistic about the future of cancer treatment and want to work towards finding new and better treatment strategies for lung and head and neck cancers through the development of our clinical trials program. We currently have several clinical trials evaluating the role of immunotherapy for the treatment of metastatic head and neck cancers open for enrollment, as well as other clinical trials focused on answering important questions regarding the management of these diseases.

Conditions I Treat

- Small cell lung cancer
- Non-small cell lung cancer
- Head and neck cancers
- Thyroid cancer

Credentials

Specialties

  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2007
MD | Albany Medical College of Union University

Post-doctoral Training & Residency

07/01/2011 - 06/30/2014
Fellowship in Medical Oncology at Yale New Haven Hospital

07/01/2008 - 06/30/2010
Residency in Internal Medicine at Rhode Island Hospital

06/20/2007 - 06/30/2008
Internship in Internal Medicine at Rhode Island Hospital

VIEW ALL expand_more

Awards

2019 - Present
Early Career Women Faculty Leadership Development Seminar
Sponsor: AAMC Application Selection Committee

2014
Annual Award for Outstanding Oncology Research
Sponsor: Yale University Medical Oncology and Hematology Fellowship
Location: New Haven, CT

2007
Albany Medical College- Distinction in Biomedical Ethics
Location: Albany, NY

VIEW ALL expand_more

Clinical Trials

A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Lead Researcher: Megan A Baumgart

This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

View Study Details

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (NRG-HN005)

Lead Researcher: Megan A Baumgart

This phase II/III trial studies how well a reduced dose of radiation therapy works with nivolumab compared to cisplatin in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer that is early in its growth and may not have spread to other parts of the body (early-stage), and is not associated with smoking. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial is being done to see if a reduced dose of radiation therapy and nivolumab works as well as standard dose radiation therapy and cisplatin in treating patients with oropharyngeal cancer.

View Study Details

Nivolumab Versus Observation in Treating Patients With Locally Advanced, Intermediate Risk HPV-Positive Oropharyngeal Cancer (EA3161)

Lead Researcher: Megan A Baumgart

This phase II/III trials studies whether maintenance immunotherapy (nivolumab) following definitive treatment with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer (throat cancer) that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy such as cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether chemotherapy and radiation therapy followed by maintenance nivolumab therapy works better than chemotherapy and radiation therapy alone in treating patients with HPV positive oropharyngeal cancer.

View Study Details

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Lead Researcher: Megan A Baumgart

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

View Study Details

EA3163 Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)

Lead Researcher: Megan A Baumgart

This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before surgery and radiation therapy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and treated with radiation.

View Study Details

CLUN18052: EA5161: Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Lead Researcher: Megan A Baumgart

If you decide to participate in this study you will be assigned to one of the two treatment groups by chance. This is done by chance because no one knows if one study group is better or worse than the other. Group 1 will receive the study drug nivolumab in combination with the usual chemotherapy regimen of platinum (cisplatin or carboplatin) and etoposide administered by an intravenous (IV) infusion. Group 2 will receive the usual chemotherapy alone administered by an intravenous (IV) infusion.

View Study Details

CHAN17022: EA3132: Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery,CHAN17022: EA3132: Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Lead Researcher: Megan A Baumgart

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if radiation therapy is more effective with or without cisplatin in treating patients with squamous cell carcinoma of the head and neck.

View Study Details

Publications

Journal Articles

2017
Baumgart, M.; Bazhenova, L.; Haggstrom, D.; Baranda, J.; Belani, C. "PUB031 PRIMAL: A Phase 1b Study of PEGPH20 plus Docetaxel in Patients with Previously Treated Hyaluronan (HA)-High Advanced NSCLC" . Journal of Thoracic Oncology. 2017; 12(1): S1465.

6/1/2015
Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN. "Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors." Cancer.. 2015 Jun 1; 121(11):1817-26. Epub 2015 Feb 03.

2015
Baumgart, M. "New molecular targets on the horizon in non-small cell lung cancer" . American Journal of Hematology and Oncology. 2015; 11(6): 10-13.

VIEW ALL PUBLICATIONS